20 May 2013
Keywords: lilly, xanomeline, eli, selective, muscarinic, m1, agonist
Article | 17 July 1995
Eli Lilly's selective muscarinic M1 agonist xanomeline has shown
efficacy in the treatment of Alzheimer's disease in a Phase II ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 July 1995
24 July 1995
© 2013 thepharmaletter.com